Scalar field exact solutions for non-flat FLRW cosmology: A technique from non-linear Schr\"odinger-type formulation

We report a method of solving for canonical scalar field exact solution in a non-flat FLRW universe with barotropic fluid using non-linear Schr\"{o}dinger (NLS)-type formulation in comparison to the method in the standard Friedmann framework. We consider phantom and non-phantom scalar field cases with exponential and power-law accelerating expansion. Analysis on effective equation of state to both cases of expansion is also performed. We speculate and comment on some advantage and disadvantage of using the NLS formulation in solving for the exact solution.Comment: 12 pages, GERG format, Reference added. accepted by Gen. Relativ. and Gra

Inflation and Braneworlds: Degeneracies and Consistencies

Scalar and tensor perturbations arising in an inflationary braneworld scenario driven by a single scalar field are considered, where the bulk on either side of the brane corresponds to Anti-de Sitter spaces with different cosmological constants. A consistency relation between the two spectra is derived and found to have an identical form to that arising in standard single-field inflation based on conventional Einstein gravity. The dS/CFT correspondence may provide further insight into the origin of this degeneracy. Possible ways of lifting such a degeneracy are discussed.Comment: 10 page

The Cholecystectomy As A Day Case (CAAD) Score: A Validated Score of Preoperative Predictors of Successful Day-Case Cholecystectomy Using the CholeS Data Set

Background Day-case surgery is associated with significant patient and cost benefits. However, only 43% of cholecystectomy patients are discharged home the same day. One hypothesis is day-case cholecystectomy rates, defined as patients discharged the same day as their operation, may be improved by better assessment of patients using standard preoperative variables. Methods Data were extracted from a prospectively collected data set of cholecystectomy patients from 166 UK and Irish hospitals (CholeS). Cholecystectomies performed as elective procedures were divided into main (75%) and validation (25%) data sets. Preoperative predictors were identified, and a risk score of failed day case was devised using multivariate logistic regression. Receiver operating curve analysis was used to validate the score in the validation data set. Results Of the 7426 elective cholecystectomies performed, 49% of these were discharged home the same day. Same-day discharge following cholecystectomy was less likely with older patients (OR 0.18, 95% CI 0.15–0.23), higher ASA scores (OR 0.19, 95% CI 0.15–0.23), complicated cholelithiasis (OR 0.38, 95% CI 0.31 to 0.48), male gender (OR 0.66, 95% CI 0.58–0.74), previous acute gallstone-related admissions (OR 0.54, 95% CI 0.48–0.60) and preoperative endoscopic intervention (OR 0.40, 95% CI 0.34–0.47). The CAAD score was developed using these variables. When applied to the validation subgroup, a CAAD score of ≤5 was associated with 80.8% successful day-case cholecystectomy compared with 19.2% associated with a CAAD score >5 (p < 0.001). Conclusions The CAAD score which utilises data readily available from clinic letters and electronic sources can predict same-day discharges following cholecystectomy

Variable-dose patient-controlled analgesia

One size of patient-controlled analgesia demand dose does not suit all patients after surgery. We have constructed a new patient-controlled analgesia system (variable-dose patient-controlled analgesia) in which patients have a choice of demand dose sizes. In an initial trial, patients could choose between 0.5, 1.0 or 1.5mg morphine. Patients readily understood the system and were all 'satisfied’ (n = 1) or‘very satisfied’ (n = 9) with the system. Only two patients sought‘complete relief from pain, most reported seeking’ moderate relief. All patients obtained‘a lot of relief or‘complete relief with this patient-controlled analgesia system. This preliminary experience suggests that variable dose patient-controlled analgesia warrants further investigation and comparison with conventional patient-controlled analgesia

A Critical Role for Extracellular DNA in Dental Plaque Formation

Extracellular DNA (eDNA) has been identified in the matrix of many different monospecies biofilms in vitro, including some of those produced by oral bacteria. In many cases, eDNA stabilizes the structure of monospecies biofilms. Here, the authors aimed to determine whether eDNA is an important component of natural, mixed-species oral biofilms, such as plaque on natural teeth or dental implants. To visualize eDNA in oral biofilms, approaches for fluorescently stained eDNA with either anti-DNA antibodies or an ultrasensitive cell-impermeant dye, YOYO-1, were first developed using Enterococcus faecalis, an organism that has previously been shown to produce extensive eDNA structures within biofilms. Oral biofilms were modelled as in vitro “microcosms” on glass coverslips inoculated with the natural microbial population of human saliva and cultured statically in artificial saliva medium. Using antibodies and YOYO-1, eDNA was found to be distributed throughout microcosm biofilms, and was particularly abundant in the immediate vicinity of cells. Similar arrangements of eDNA were detected in biofilms on crowns and overdenture abutments of dental implants that had been recovered from patients during the restorative phase of treatment, and in subgingival dental plaque of periodontitis patients, indicating that eDNA is a common component of natural oral biofilms. In model oral biofilms, treatment with a DNA-degrading enzyme, NucB from Bacillus licheniformis, strongly inhibited the accumulation of biofilms. The bacterial species diversity was significantly reduced by treatment with NucB and particularly strong reductions were observed in the abundance of anaerobic, proteolytic bacteria such as Peptostreptococcus, Porphyromonas and Prevotella. Preformed biofilms were not significantly reduced by NucB treatment, indicating that eDNA is more important or more exposed during the early stages of biofilm formation. Overall, these data demonstrate that dental plaque eDNA is potentially an important target for oral biofilm control. </jats:p